Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine in Breast Cancer Surgery
NCT03108937Completed
- Sponsor
- Renji Hospital
- Start
- Apr 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of dexmedetomidine in breast cancer (2 arms), sponsored by Renji Hospital. Primary endpoint: Cell Proliferation at 24 hours. Started Apr 2017; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03108937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03108937.